EIGR
Closed
Eiger Biopharmaceuticals Inc
2.2725
+2.2725 (0%)
Last Update: 10 May 2024 16:30:00
Yesterday: 0.
Day's Range: 2.27 - 2.2725
Send
sign up or login to leave a comment!
When Written:
0.8969
Eiger Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for rare and ultra-rare diseases. The company's pipeline includes treatments for hepatitis delta virus (HDV), pulmonary arterial hypertension (PAH), lymphedema, and COVID-19. Eiger's lead product candidate, lonafarnib, is being developed as a potential treatment for HDV, a severe form of viral hepatitis that affects approximately 15 million people worldwide. The company is also developing avexitide for the treatment of post-bariatric hypoglycemia, ubenimex for lymphedema, and Zokinvy for PAH. Eiger is headquartered in Palo Alto, California, and was founded in 2008.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








